-
If you're attending
#SynBioBeta2019 don't miss#ActoBio Therapeutics™ CEO Pieter Rottiers' overview of the innovative#ActoBiotics® platform and its applications on October 1. Read more: http://actobio.com , follow us on Linkedin or Twitter@ActobioT#biotech#immunologypic.twitter.com/3RBSchnWqA
-
Who said
#cheese wasn't good?
#diabetes#ActoBio#biotechhttps://goo.gl/jTiXa9 -
#ActoBio Receives#IND#Approval for New#Antigen-Specific#Immunotherapy Study#Designed to#Improve#Gluten#Tolerance in#Patients with#Celiac https://www.trialsitenews.com/actobio-receives-ind-approval-for-new-antigen-specific-immunotherapy-study-designed-to-improve-gluten-tolerance-in-patients-with-celiac/ … via@Trial Site News#healthcare@ActoBio -
REMINDER: Intrexon will host two presentations this week. A live webcast of the presentations will be available on the Investors section of Intrexon's website at http://investors.dna.com/events . Please share.
#JPM18#JPMWeek#BTS18#BioweekSF#ActoBio#Precigen#Healthcare#XONpic.twitter.com/c6qiJ9t69E
-
Nice update in
#T1D from Actobio Therapeutics !#Actobio using former@ActoGeniX technology ... https://labiotech.eu/actobio-type-1-diabetes-bacteria/ … -
A new milestone in the treatment of
#T1D ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes. full press release: http://www.actobio.com/T1DActoBio.pdf#actobio#diabetes#biotechnology#innovation#WeWontRest@ActobioTpic.twitter.com/YusJmyiq4p
-
ActoBio Therapeutics' CEO Pieter Rottiers will participate in a panel discussion entitled “Evaluation of Combination Therapies to Address Unmet Clinical Needs” on THU March 28th at 14:30 PM. https://lnkd.in/gx-j3YW
#immunotherapy#actobio#actobiotics#biopharmaceuticals#scicommpic.twitter.com/3YPOf0RwLJ
-
Breaking: intrexon announces 4 presentations at upcoming investor conferences. Discover more: https://bit.ly/2F4a5sy
$XON#Precigen#ActoBio#Xogenex#JPM19#BiotechShowcasepic.twitter.com/ikeuy6Wl9o
-
ICYMI: Replay of the Biotech Showcase 2018 Conference presentation by Pieter Rottiers, PhD, ActoBio's CEO, is now available on demand on the Investors section of Intrexon's website at http://bit.ly/2m2BuAe .
#BTS18#BioweekSF#ActoBio#Xon#healthcarepic.twitter.com/ACJxjMmJNC
-
The Future of Diabetes Treatment: Is a Cure Possible? https://labiotech.eu/features/diabetes-treatment-cure-review/ …
#actobio@ActobioT#T1D#biotech#therapy@flandersbio -
-
At
#SynBioBeta? Don't miss#ActoBio Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: http://www.actobio.com or follow on Twitter@ActobioT or LinkedIn.#actobiotics#healthcare#biotechpic.twitter.com/CuLsXpxme1
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.